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Abstract Most information on the dose–response of
radiation-induced cancer is derived from data on the
A-bomb survivors who were exposed to c-rays and neu-
trons. Since, for radiation protection purposes, the dose
span of main interest is between 0 and 1 Gy, the analysis of
the A-bomb survivors is usually focused on this range.
However, estimates of cancer risk for doses above 1 Gy are
becoming more important for radiotherapy patients and for
long-term manned missions in space research. Therefore in
this work, emphasis is placed on doses relevant for radio-
therapy with respect to radiation-induced solid cancer. The
analysis of the A-bomb survivor’s data was extended by
including two extra high-dose categories (4–6 Sv and
6–13 Sv) and by an attempted combination with cancer
data on patients receiving radiotherapy for Hodgkin’s dis-
ease. In addition, since there are some recent indications
for a high neutron dose contribution, the data were fitted
separately for three different values for the relative bio-
logical effectiveness (RBE) of the neutrons (10, 35 and
100) and a variable RBE as a function of dose. The data
were fitted using a linear, a linear-exponential and a pla-
teau-dose–response relationship. Best agreement was found
for the plateau model with a dose-varying RBE. It can be
concluded that for doses above 1 Gy there is a tendency for
a nonlinear dose–response curve. In addition, there is
evidence of a neutron RBE greater than 10 for the A-bomb
survivor data. Many problems and uncertainties are
involved in combing these two datasets. However, since
very little is currently known about the shape of dose–
response relationships for radiation-induced cancer in the
radiotherapy dose range, this approach could be regarded
as a first attempt to acquire more information on this area.
The work presented here also provides the first direct
evidence that the bending over of the solid cancer excess
risk dose response curve for the A-bomb survivors, gen-
erally observed above 2 Gy, is due to cell killing effects.
Introduction
The dose–response relationship for radiation carcinogenesis
up to 1 or 2 Gy has been quantified in several major analyses
of the atomic bomb survivors data; recently papers have
been published, for example, by Preston et al. [1, 2] and
Walsh et al. [3, 4]. This dose range is important for radiation
protection purposes where low doses are of particular
interest. However, it is also important to know the shape of
the dose–response curve for radiation-induced cancer for
doses above 1 Gy. In patients who receive radiotherapy,
parts of the patient volume can receive high doses and it is
therefore of great importance to know the risk for the patient
to develop a cancer which could have been caused by the
radiation treatment. In addition, the health risk to astronauts
from space radiation is recognized as one of the limiting
factors for long-term space missions. During solar events
astronauts can receive doses which are above 1 Gy [5, 6].
The shape of the dose–response curve for radiation-
induced cancer is currently of much debate [7–16]. It is not
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known whether cancer risk as a function of dose continues
to be linear or decreases at high dose due to cell killing or
levels off due to, for example, a balance between cell
killing and repopulation effects. The work presented here,
aims to clarify the dose–response shape for doses above
1 Gy. In this dose range, data are available from the atomic
bomb survivors from Hiroshima and Nagasaki, although
the data pertaining to doses above 4 Gy have not usually
been included in previous analyses, due to the associated
large uncertainties. In addition, data are available from
about 30,000 patients with Hodgkin’s disease who were
irradiated with localized doses of up to around 40 Gy. The
aim of this paper is to attempt a combination of the epi-
demiological data from the atomic bomb survivors and the
Hodgkin data, in order to determine a possible dose–
response relationship for radiation-induced solid cancer for
radiotherapy doses. Many problems and uncertainties (see
‘‘Discussion’’ section) are involved in combing these two
datasets. However, since very little is currently known
about the shape of dose–response relationships for radia-
tion-induced cancer in the radiotherapy dose range, this
approach could be regarded as a first attempt to acquire
more information on this area.
Materials and methods
Modeling of the atomic bomb survivors data
The most recent data for all solid cancers incidences
relating to the follow-up period from 1958 to 1998 and
with DS02 doses (which is publicly available from the
Radiation Effects Research Foundation—RERF, web site:
http://www.rerf.or.jp) were analyzed here [1]. Computa-
tions were performed with respect to the organ-averaged
weighted doses because reference to the colon weighted
dose, which is supplied in the standard dataset for use in
the analysis of all solid cancers combined, is known to
underestimate the average dose to all organs [17]. The
organ-averaged doses are calculated with weighting factors
accounting for the risk contribution of individual tumor
sites. The weighted organ-averaged doses are greater than
the colon doses (which are used in the RERF analyses) by
factors of 1.085 and 2 for the gamma and neutron contri-
butions, respectively.
Data of 281 survivors (out of a total of 86,611) with
doses varying from 4 to 13 Gy were included with the main
data of doses between 0 and 4 Gy in the present analysis.
The high-dose data were regrouped into organ-averaged
absorbed dose categories of 4–6 Gy and 6–13 Gy. All
doses were adjusted to allow for random errors in dose
estimates by the method of Pierce et al. 1990 [18].
The excess absolute risk (EAR) models were optimized
against the epidemiological data, by the maximum likeli-
hood Poisson regression method employing the EPICURE-
AMFIT software [3]. Although the baseline rates can be
dealt with stratification, the main calculations here adopt
the fully parametric baseline model of Preston et al. [1].
Since there are some recently discovered indications of a
high neutron dose contribution [19, 20], the data were fitted
separately for three different values for the relative bio-
logical effectiveness of neutrons (10, 35 and 100). In
addition, a dose dependent RBED for neutrons determined
by Sasaki et al. [21] using the kerma-weighted chromo-
somal effectiveness of A-bomb spectrum energy photons
was used (Eq. 9 in [21]). When applying Sasaki’s equation
the maximum RBE of the neutrons at the low-dose limit is
75.1.
The EAR models applied here were the same as those
already considered and explained in detail [1, 2]. Here
organ-averaged weighted dose D is the sum of the c-ray
dose and the RBE-weighted neutron dose. The differences
between the previous [2] and present work are that the input
data include two extra high-dose categories; organ-average
weighted doses are applied instead of colon-weighted
doses; a range of neutron weighting factors (RBEs) are
considered; and different forms of dose–response relation-
ships, which are more suitable for the high-dose data, i.e. a
linear-exponential and a plateau model are employed.
The excess absolute risk is factorized into a function of
dose f(D) and a modifying function that depends on the
variables gender (s) and age at exposure (e) and age
attained (a):
EAR D; e; a; sð Þ ¼ bf Dð Þl e; a; sð Þ ð1Þ
where b is the initial slope and l the modifying function
containing the population dependent variables:
l e; a; sð Þ ¼ exp ce e 37ð Þ þ ca ln
a
46
  
1 sð Þ
þfor females;for malesð Þ
ð2Þ
In this form the fit parameters are gender-averaged and
centered at an age at exposure (e) of 37 years and an attained
age (a) of 46 years, since these are the characteristic ages of
the Hodgkin’s patient population as described in the next
section. However, the centering is not critical to the fitting
procedure and the resulting risks can be scaled to gender-
specific values for any values of the two age variables.
It should be noted here that the dose-dependent part f(D)
of Eq. (1), which is, to a first approximation, population-
independent is sometimes called organ equivalent dose
(OED) [13], when averaged over the whole body volume.
For highly inhomogeneous dose distributions, cancer risk is
proportional to average dose only for a linear dose–
response relationship. For any other dose–response
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relationship the OED in the body is proportional to cancer
risk, if it is defined as
OED ¼ 1
V
X
i
Vif Dið Þ ð3Þ
where V is the total body volume and the sum is taken over
all volume elements Vi with homogenous dose. The OED is
hence a dose–response weighted dose variable, which is
proportional to cancer risk in one population (same gender,
age at exposure and age attained). This quantity allows
comparisons of, e.g. dose distributions in a radiotherapy
patient with respect to radiation induced cancer.
Three different dose–response relationships are consid-
ered here. The first is a linear response over the whole dose
range:
OED ¼ 1
V
X
i
ViDi ð4Þ
The second is a linear-exponential dose–response
relationship of the form:
OED ¼ 1
V
X
i
ViDi exp aDið Þ ð5Þ
and the third is a dose–response, which is flattening at high
dose, a so-called plateau dose–response [9] described by:
OED ¼ 1
V
X
i
Vi
1 exp dDið Þð Þ
d
ð6Þ
All of the dose–response curves defined by Eqs. (4)–(6)
become, in the limit of small dose:
lim
D!0
OED ¼ 1
V
X
i
ViDi ¼ D ð7Þ
Hence the OED is, in the case of a homogenous distribution
of small dose, average absorbed organ dose, which is
consistent with radiation protection schemes.
It should be noted here that it is possible to define a
homogenous organ dose, OHD, which would result in the
same radiation-induced cancer rate as the inhomogenous
dose distribution. OHD is then, for the linear-exponential
model, simply the inverse function of Eq. (5):
OHD ¼  1
a
LambertW aOEDð Þ ð8Þ
where LambertW is the Lambert-function. For a plateau
dose–response relationship, the corresponding homogenous
dose is:
OHD ¼  1
d
ln 1 dOEDð Þ ð9Þ
When applying a dose–response model which is linear
in dose, even for large doses Eq. (4), the OHD is simply the
mean dose.
The data were also test-fitted using a linear-quadratic-
exponential EAR model. However, the fit parameters
relating to the quadratic term in dose were not found to be
statistically significantly determined (in contrast to previ-
ous results for the lower dose range of 0–2 Sv for excess
relative risk models, [3]) indicating that a linear-exponen-
tial dose–response curve may be a better representation of
the dose response than a linear-quadratic-exponential
dose–response, when the data pertaining to high doses are
included in the analysis.
Modeling of the Hodgkin’s patients
Cancer risk is only proportional to average organ dose as
long as the dose–response curve is linear. At high dose it
could be that the dose–response relationship is nonlinear and
as a consequence, OED replaces average dose to quantify
radiation-induced cancer. In order to calculate OED in
radiotherapy patients, information on the three-dimensional
dose distribution is necessary. This information is usually not
provided in epidemiological studies on second cancers after
radiotherapy. However, in Hodgkin’s patients the three-
dimensional dose distribution can be reconstructed.
For this purpose data on secondary cancer incidence
rates in various organs for Hodgkin’s patients treated with
radiation were also included in this analysis. Data on
Hodgkin’s patients treated with radiation seem to be ideal
for an attempted combination with the A-bomb data. These
patients were treated at a relatively young age, with cura-
tive intent and hence secondary cancer incidence rates for
various organs are known with a good degree of precision.
Since the treatment of Hodgkin’s disease with radiotherapy
has been highly successful in the past, the treatment tech-
niques have not been modified very much over the last
30 years. This can be verified, for example, by a compar-
ison of the treatment planning techniques used from 1960
to 1970 [22] with those used from 1980 until 1990 [23].
Additionally, the therapy protocols do not differ very much
between the institutions that apply this form of treatment.
These factors make it possible to reconstruct a statistically
averaged OED distribution for each dose–response model
f(D), which is characteristic for a large patient collective of
Hodgkin’s disease patients.
The overall risk of selected second malignancies of
32,591 Hodgkin’s patients after radiotherapy has been
quantified by Dores et al. [24]. They found, for all solid
cancers after the application of radiotherapy as the only
treatment, an excess absolute risk of 39 per 10,000 patients
per year (with a 95% confidence interval ranging from 35.4
to 40.5). The total number of person years in these studies
was 92,039 with a mean patient age at diagnosis of
37 years. In combining the Hodgkin data with the A-bomb
Radiat Environ Biophys (2008) 47:253–263 255
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survivor data ‘‘age at diagnosis of Hodgkin’s disease’’ was
equated to ‘‘age at exposure to the A-bomb’’, and ‘‘age at
diagnosis of Hodgkin’s disease + follow-up-time’’ was
equated to ‘‘attained age of A-bomb survivors’’. The fol-
low-up time distribution of the Hodgkin’s patients [24] can
be used with the temporal patterns of the atomic bomb data
of Eq. (2) to obtain the mean attained age (a = 46 years).
The mean age at exposure and mean attained age for the
Hodgkin population was then used to center the fit of the
A-bomb survivor data.
In several studies, no increased risk of solid cancers
overall was observed after the application of chemotherapy
alone. Dores et al. calculated the solid cancer risk both, after
radiotherapy alone and combined modality therapy, and
found an excess absolute risk of 43 per 10,000 patients per
year for the latter. As a consequence, the difference in risk
between combined modality treatment and radiotherapy
alone (4 per 10,000 patients per year) can be tentatively
attributed to either chemotherapy or a genetic susceptibility
of the Hodgkin patient population with regard to cancer or
both. For this reason, we used this risk difference as an error
estimate for the subsequent analysis.
A statistically averaged dose distribution was recon-
structed, which is characteristic for a large patient
collective of Hodgkin’s disease patients in the Zubal
Phantom, a voxel-based anthropomorphic phantom [25].
Different treatment plans for the various patterns of lymph
nodes involvement [26] were obtained. The dose distribu-
tions were converted into OED according to Eqs. (4)–(6),
assuming a mechanistic approach of cancer risk, where it is
assumed that the total risk is the volume-weighted sum of
the risks of the partial volumes. A statistically averaged
OED distribution was then obtained by combining the OED
from different plans with respect to the statistical weight of
the involvement of the individual lymph nodes [26].
Details of the treatment plans were taken from the review
by Hoppe [23]. The Eclipse External Beam Planning sys-
tem version 6.5 (Varian Oncology Systems, Palo Alto, CA)
was used for treatment planning with corrected dose dis-
tributions for head-, phantom- and collimator-scatter also
including the extremities. Three different treatment plans
were computed which included a mantle field, an inverted-
Y field and a para-aortic field. All plans were calculated
with 6 MV photons and consisted of two opposed fields.
The prescribed dose was 36 Gy. The OED representing the
risk for all solid cancers was finally determined as the
average OED in the whole Zubal phantom.
Combined fit of A-bomb survivor and Hodgkin’s
patients
Since the dose distribution in a Hodgkin’s patient is highly
inhomogenous and the dose–response relationships as
described by Eqs. (5)and (6) are nonlinear, it is not
appropriate to apply a straight forward fit to the data. An
iterative fitting procedure needs to be used instead. For this
purpose, as described in the last section, the whole three-
dimensional dose distribution used for Hodgkin treatment
was converted into an OED-distribution for given model
parameters a or d. In addition, the dose data of the atomic
Table 1 Population-dependent variables with one standard deviation in brackets applying the EPICURE-AMFIT code to the atomic survivor
data
RBE
10 35 100 RBED
Gender s 0.1686 (0.070) 0.1707 (0.070) 0.1742 (0.071) 0.1704 (0.071)
Age at exposure ce -0.0285 (0.006) -0.0280 (0.006) -0.0273 (0.006) -0.0277 (0.006)
Attained ca 2.408 (0.273) 2.423 (0.274) 2.432 (0.277) 2.409 (0.274)
Table 2 Results of the fit to the atomic bomb data only. In brackets
one standard deviation is given
RBE Model
parameter
Linear Linear-
exponential
Plateau
10 bb 9.572 (3.84) 14.201 (0.95) 14.348 (0.94)
aa – 0.089 (0.024) –
da – – 0.206 (0.027)
P value [0.5 [0.5 \0.01
35 bb 7.093 (4.08) 11.815 (0.84) 12.259 (0.81)
aa – 0.082 (0.021) –
da – – 0.202 (0.023)
P value [0.5 [0.5 \0.01
100 bb 4.030 (3.83) 8.365 (0.66) 8.873 (0.65)
aa – 0.066 (0.017) –
da – – 0.178 (0.018)
P value [0.5 [0.5 0.751
RBED b
b 8.813 (2.33) 11.710 (0.74) 11.790 (0.76)
aa – 0.064 (0.020) –
da – – 0.143 (0.021)
P value [0.5 0.477 \0.01
The P value was calculated using a v2-statistic with 21 degrees of
freedom
a in Gy-1
b in (10,000 PY Gy)-1
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bomb survivors were converted to OED using Eqs. (5) and
(6), and a homogenous whole body irradiation of the sub-
jects was assumed. Since EAR as a function of OED is by
definition linear Eq. (1), a linear curve was fitted to the
combined dataset. The fitted EAR values were compared to
the original data and weighted with the inverse of their
variances. The a- and d-values were fitted iteratively by
minimizing v2
Fig. 1 Plot of cancer incidence
per 10,000 persons per year as a
function of organ equivalent
dose (OED) of the A-bomb
survivors (as squares) and the
Hodgkin’s patients (as a
diamond). a, c, e and g show the
fit to the A-bomb survivor data
using a linear-exponential
model and b, d, f and h using a
plateau-dose model. The data
and fits are presented for four
different neutron RBE models
and for age at exposure of
37 years and attained age of
46 years
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v2 ¼
X EARj  EARfitj
rj
 !2
ð10Þ
where rj is the standard deviation of each data point and
the sum includes both the A-bomb and the Hodgkin data.
The combination of the A-bomb survivor data with the
Hodgkin’s patients data made it necessary to use a fitting
procedure other than the EPICURE-AMFIT software. To
be consistent throughout b, a and d for the A-bomb sur-
vivors data were re-fitted using the above-mentioned fitting
routine. Since the re-fitted parameters agree within their
standard errors with results using the EPICURE-AMFIT
software, only the results of the re-fits are given here.
Results
Fits to A-bomb survivors data alone
Fitting the EAR model dose modifying function Eq. (2)
with EPICURE-AMFIT to the atomic survivor data yields
the population-dependent variables listed with the standard
deviations in Table 1.
If a simple linear fit is optimized against the data, it is
possible to determine the initial slope b for a neutron
RBE = 10, 35, 100 and RBED. The data are listed together
with the corresponding standard deviations and P values in
Table 2. The P values were obtained by applying a v2-
statistic with 21 degrees of freedom applied to the com-
plete dataset (A-bomb survivors and Hodgkin data). Values
for b for a linear-exponential fit and for plateau-fit to the A-
bomb survivors are also given in Table 2. The linear-
exponential and plateau-fits for all four neutron RBE val-
ues considered here are plotted in Fig. 1.
Fits to the Hodgkin’s data alone
Since in the limit of small dose both, the linear-exponential
and the plateau-dose–response curve, as described by Eqs.
(5) and (6), respectively, become linear with dose, the
initial slope b is by definition the same as that required for
application with small doses in radiation protection. For
this reason, the initial slope is taken from the fits to the A-
bomb survivors of Table 2. The remaining model param-
eters a and d, were then determined by an iterative fit to the
Hodgkin’s data point. For the linear fit, an initial slope of
3.016 is obtained independently of the neutron RBE. The
linear-exponential fit results in a and d values, which are
listed in Table 3 and plotted in Fig. 2 for the different
values of the neutron RBE considered here.
Fits to A-bomb and Hodgkin’s data combined
The combined dataset of A-bomb survivors data and
Hodgkin’s patients were fitted iteratively. The model
parameters together with their standard deviations and the
P values are listed in Table 4. The fitted functions are
plotted in Fig. 3.
Discussion
The epidemiological data from the A-bomb survivors and
the Hodgkin’s patients are associated with large errors as
discussed below. Nevertheless, some basic conclusion can
be tentatively drawn from the analysis presented here. The
quality of the applied fits measured by the P value (listed in
Tables 2–4) shows that the linear model does not describe
the data as well as the two other models. It seems that for
doses above 4 Gy, the dose–response relationship is flat-
tening. However, there is not much difference between the
linear-exponential and the plateau-dose–response relation-
ships, regarding their quality of fit. Both models fit the data
well with a slight advantage for the plateau model.
It has been observed [17, 27] that cancer risks for
patients exposed to ionizing radiation in the treatment of
Table 3 Results of the fit to the Hodgkin’s data only
RBE Model
parameter
Linear Linear-
exponential
Plateau
10 bb 3.016 (0.31) 14.201 (0.82) 14.378 (0.90)
aa – 0.055 (0.018) –
da – – 0.180 (0.023)
P value [0.5 \0.01 \0.01
35 bb 3.016 (0.31) 11.815 (0.69) 12.259 (0.75)
aa – 0.047 (0.014) –
da – – 0.150 (0.018)
P value [0.5 \0.01 \0.01
100 bb 3.016 (0.31) 8.365 (0.51) 8.873 (0.54)
aa – 0.034 (0.010) –
da – – 0.100 (0.011)
P value [0.5 0.061 0.013
RBED b
b 3.016 (0.31) 11.710 (0.70) 11.790 (0.75)
aa – 0.047 (0.018) –
da – – 0.140 (0.020)
P value [0.5 \0.01 \0.01
For the linear-exponential and the Plateau-model the initial slope of
the atomic bomb data fit is used (Table 2). In brackets one standard
deviation is given. The P value was calculated using a v2-statistic
with 22 degrees of freedom
a in Gy-1
b in (10,000 PY Gy)-1
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cancer, are generally lower (when plotted against average
absorbed dose, not OED) than those estimated from the
A-bomb survivors. It was suggested that cell sterilization,
dose fractionation or a larger neutron RBE in the A-bomb
data could account for this difference. The present anal-
ysis using OED, which includes cell sterilization effects,
shows good agreement with the A-bomb data which are
plotted as a function of absorbed dose for a RBE of 10
Fig. 2 Plot of cancer incidence
per 10,000 persons per year as a
function of organ equivalent
dose (OED) of the atomic bomb
survivors (as squares) and the
Hodgkin’s patients (as a
diamond). a, c, e and g show the
fit to the Hodgkin’s patients
using a linear-exponential
model and b, d, f and h using a
plateau-dose model. The data
and fits are presented for four
different neutron RBE models
and for age at exposure of
37 years and attained age of
46 years
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and for Sasaki’s RBE in Fig. 4. It has often been
hypothesized that the bending-over, of the solid cancer
excess risk dose–response curve for the A-bomb survi-
vors, that has been observed to occur above 2 Gy, could
be due to cell killing effects. The work presented here
might provide the first direct evidence for this. The
impact of dose fractionation and repopulation is not
included in the present analysis.
The average doses in the two highest-weighted dose
categories are increased from 5.4 and 8.9 Sv for a RBE 10
up to 12.7 and 22.1 Sv for a RBE of 100, respectively.
Since the data in these high dose categories are subject to
very large errors (standard deviation 0.8 and 2.3 Sv for
RBE = 10, and 6.1 and 12.3 Sv for RBE = 100), it is not
possible to assess the degree of dependability of the
assumption of a large neutron RBE values such as 100, if
the mean doses in these dose categories are compared with
the lethal doses for humans (LD50). Additionally, it is
worth noting that the last dose category employed here has
been omitted in all previous analyses of these data, since
the small chance of survival suggests that estimates of
doses in this upper group could possibly be too large [18].
Sasaki’s formulation of a neutron RBE which is variable
with dose results in a dose–response curve which fits the
data well and the average dose in the two highest dose
categories is only increased to 5.7 and 9.0 Sv. This could
be an additional indication for a dose-dependent neutron
RBE.
Increased risks of solid cancers after Hodgkin’s disease
have been generally attributed to radiotherapy. An impor-
tant question is whether chemotherapy for Hodgkin’s
disease also adds to the solid cancer risk, and if so, at which
sites. If chemotherapy indeed affects induction of solid
tumors, one would expect that patients receiving combined
modality treatment would have a greater relative risk than
patients treated with radiotherapy alone. Only one study
has reported a significantly greater risk for solid cancers
overall after combined chemo- and radiotherapy compared
with irradiation alone [28], whereas no such difference has
been found in the majority of investigations [28]. However,
for selected solid cancer sites larger (e.g. lung) or lower
(e.g. breast) risks were observed after combined modality
treatment than after irradiation alone [28]. It can be ten-
tatively hypothesized, for the analysis presented here, that
cancer risk after chemotherapy of disparate sites is bal-
anced in such a way that the risk for all solid tumors is not
affected [28].
It is well known that genetic susceptibility underlies
Hodgkin’s disease [29]. It is not clear whether this genetic
susceptibility would also affect the development of other
cancers. There is the possibility of a cancer diathesis, the
prospect that, for some reasons related to genetic makeup, a
person who developed one cancer has an inherently
increased risk of developing another. However, such cancer
susceptibility would result in a minimal excess cancer
incidence compared to the incidence of radiation related
tumors, since such an excess cancer incidence of solid
tumors should also be seen in Hodgkin’s patients after
treatment with chemotherapy alone. However, there is no
statistically significant increase for all solid tumors com-
bined. Therefore, such an effect will be hidden in the 95%
confidence interval of the observed cancer incidence after
chemotherapy.
In this work, EAR has been used to quantify radiation-
induced cancer. Usually ERR is recommended for trans-
ferring risk from the Japanese population to other
populations. EAR is used here, since the risk calculations
of the Hodgkin’s cohort are based on extremely inhom-
ogenous dose distributions. It is assumed that the total
absolute risk in the whole body is the volume-weighted
sum of the risks of the partial volumes which are irradiated
homogenously. Currently, there is no available method for
obtaining analogous whole-body risk using ERR. Since the
difference between the Japanese and the US population in
EAR for all solid tumors is less than 10% and only all solid
tumors together were analyzed here, the use of EAR is
probably justifiable.
Table 4 Results of the fit to the atomic bomb data and the Hodgkin’s
data combined
RBE Model
parameter
Linear Linear-
exponential
Plateau
10 bb 4.170 (9.01) 12.367 (0.81) 13.824 (0.90)
aa – 0.050 (0.018) –
da – – 0.179 (0.023)
P value [0.5 \0.01 \0.01
35 bb 4.140 (6.86) 9.877 (0.68) 10.966 (0.75)
aa – 0.043 (0.014) –
da – – 0.146 (0.018)
P value [0.5 \0.01 \0.01
100 bb 3.522 (4.20) 6.689 (0.51) 7.205 (0.56)
aa – 0.034 (0.010) –
da – – 0.111 (0.012)
P value [0.5 0.053 0.168
RBED b
b 4.184 (6.72) 10.774 (0.70) 11.677 (0.70)
aa – 0.044 (0.017) –
da – – 0.139 (0.019)
P value [0.5 \0.01 \0.01
In brackets one standard deviation is given. The P value was calcu-
lated using a v2-statistic with 22 degrees of freedom
a in Gy-1
b in (10,000 PY Gy)-1
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Conclusions
A comparison of dose distributions in humans, for example
in radiotherapy treatment planning, with regard to cancer
incidence or mortality can be performed by computing
OED, which can be based on any dose–response relation-
ship. In this work, OED was defined for a linear Eq. (4), a
linear-exponential Eq. (5) and a plateau dose–response
relationship Eq. (6). The model parameters (a and d) were
obtained by a fit of these OED models to A-bomb survivors
Fig. 3 Plot of cancer incidence
per 10,000 persons per year as a
function of organ equivalent
dose (OED) of the atomic bomb
survivors (as squares) and the
Hodgkin’s patients (as a
diamond). a, c, e and g show the
fit to the combined dataset of A-
bomb survivor data and
Hodgkin’s patients using a
linear-exponential model and b,
d, f and h using a plateau-dose
model. The data and fits are
presented for four different
neutron RBE models and for
age at exposure of 37 years and
attained age of 46 years
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and Hodgkin’s patients data and are listed in Table 3. For
any three-dimensional inhomogenous dose distribution,
cancer risk can be compared by computing OED using the
coefficients obtained in this work.
For absolute risk estimates, EAR can be determined by
taking additionally the fitted initial slope b from Table 3
and multiplying it with the population-dependent modify-
ing function Eq. (1) using the fitted coefficients of Table 1.
However, absolute risk estimates must be viewed with
care, since the errors involved are large.
It has often been hypothesized that the bending over, of
the solid cancer excess risk dose response curve for the A-
bomb survivors, that has been observed to occur above
2 Gy, could be due to cell killing effects. The work pre-
sented here might provide the first direct evidence for this.
Acknowledgments Special thanks are due to Dr. Werner Ru¨hm for
many useful comments and valuable discussions. This work makes
use of the data obtained from the Radiation Effects Research Foun-
dation (RERF) in Hiroshima, Japan. RERF is a private foundation
funded equally by the Japanese Ministry of Health and Welfare and
the US Department of Energy through the US National Academy of
Sciences. The conclusions in this work are those of the authors and do
not necessarily reflect the scientific judgment of RERF or its funding
agencies.
References
1. Preston DL, Ron E, Tokuoka S, Funamoto S, Nishi N, Soda M,
Mabuchi K, Kodama K (2007) Solid cancer incidence in atomic
bomb survivors: 1958–1998. Radiat Res 168:1–64
2. Preston DL, Pierce DA, Shimizu Y, Cullings HM, Fujita S,
Funamoto S, Kodama K (2004) Effects of recent changes in
Atomic bomb survivor dosimetry on cancer mortality risk esti-
mated. Radiat Res 162:377–389
3. Walsh L, Ru¨hm W, Kellerer AM (2004) Cancer risk estimates for
X-rays with regard to organ specific doses, part I: all solid cancers
combined. Radiat Environ Biophys 43:145–151
4. Walsh L, Ru¨hm W, Kellerer AM (2004) Cancer risk estimates for
c-rays with regard to organ specific doses, part II: site specific
solid cancers. Radiat Environ Biophys 43:225–231
5. Cucinotta FA, Wu H, Shavers M, George K (2003) Radiation
dosimetry and biophysical models of space radiation effects.
Gravit Space Biol Bull 16(2):11–18
6. Kim MH, Cucinotta FA, Wilson JW (2007) A temporal forecast
of radiation environments for future space exploration missions.
Radiat Environ Biophys 46(2):95–100
7. Lindsay KA, Wheldon EG, Deehan C, Wheldon TE (2001)
Radiation carcinogenesis modelling for risk of treatment-related
second tumours following radiotherapy. Br J Radiol
74(882):529–536
8. Hall EJ, Wuu CS (2003) Radiation-induced second cancers: the
impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys
56(1):83–88
9. Davis RH (2004) Production and killing of second cancer pre-
cursor cells in radiation therapy. Int J Radiat Oncol Biol Phys
59(3):916
10. Schneider U (2005) Dose–response relationship for radiation-
induced cancer-decrease or plateau at high dose. Int J Radiat
Oncol Biol Phys 61(1):312–313
11. Dasu A, Toma-Dasu I (2005) Dose-effect models for risk-
relationship to cell survival parameters. Acta Oncol 44(8):829–
835
12. Dasu A, Toma-Dasu I, Olofsson J, Karlsson M (2005) The use of
risk estimation models for the induction of secondary cancers
following radiotherapy. Acta Oncol 44(4):339–347
13. Schneider U, Zwahlen D, Ross D, Kaser-Hotz B (2005) Esti-
mation of radiation induced cancer from 3D-dose distributions:
concept of organ equivalent dose. Int J Radiat Oncol Biol Phys
61: 1510–1515
14. Schneider U, Kaser-Hotz B (2005) A simple dose–response
relationship for modelling secondary cancer incidence after
radiotherapy. Z Med Phys 15(1):31–37
15. Sachs RK, Brenner DJ (2005) Solid tumor risks after high doses
of ionizing radiation. Proc Natl Acad Sci USA 102(37):13040–
13045
16. Schneider U, Kaser-Hotz B (2005) Radiation risk estimates after
radiotherapy: application of the organ equivalent dose concept to
plateau dose–response relationships. Radiat Environ Biophys
44(3):235–2399
17. Kellerer AM, Walsh L (2001), Risk estimation for fast neutrons
with regard to solid cancer. Radiat Res 156:708–717
Fig. 4 Plot of cancer incidence per 10,000 persons per year as a
function of organ absorbed dose of the atomic bomb survivors (as
squares). Shown are the fits to the combined dataset of A-bomb
survivor data and Hodgkin’s patients using a linear-exponential model
(solid line) and a plateau-dose model (dashed line). The data and fits
are presented for a neutron RBE of 10 (a) and for a varying RBED (b)
262 Radiat Environ Biophys (2008) 47:253–263
123
18. Pierce DA, Stram DO, Vaeth M (1990) Allowing for random
errors in radiation dose estimates for the atomic bomb survivor
data. Radiat Res 123:275–284
19. Kellerer AM, Ru¨hm W, Walsh L (2006) Indications of the neu-
tron effect contribution in the solid cancer data of the A-bomb
survivors. Health Phys 90(6):554–564
20. Ru¨hm W, Walsh L (2007) Current risk estimates based on the A-
bomb survivors data—a discussion in terms of the ICRP rec-
ommendations on the neutron weighting factor. Radiat Prot
Dosimetry. (Advance access, May 28, doi:10.1093/rpd/ncm087)
21. Sasaki MS, Endo S, Ejima Y, Saito I, Okamura K, Oka Y, Hoshi
M (2006) Effective dose of A-bomb radiation in Hiroshima and
Nagasaki as assessed by chromosomal effectiveness of spectrum
energy photons and neutrons. Radiat Environ Biophys 45:79–91
22. Carmel RJ, Kaplan HS (1976) Mantle irradiation in Hodgkin’s
disease. An analysis of technique, tumor eradication, and com-
plications. Cancer 37(6):2813–2825
23. Hoppe RT (1990) Radiation therapy in the management of
Hodgkin’s disease. Semin Oncol 17(6):704–715
24. Dores GM, Metayer C, Curtis RE, Lynch CF, Clarke EA,
Glimelius B, Storm H, Pukkala E, van Leeuwen FE, Holowaty
EJ, Andersson M, Wiklund T, Joensuu T, van’t Veer MB, Stovall
M, Gospodarowicz M, Travis LB (2002) Second malignant
neoplasms among long-term survivors of Hodgkin’s disease: a
population-based evaluation over 25 years. J Clin Oncol
20(16):3484–3494
25. Zubal IG, Harrell CR, Smith EO, Rattner Z, Gindi G, Hoffer PB
(1994) Computerized three-dimensional segmented human anat-
omy. Med Phys 21(2):299–302
26. Mauch PM, Leslie AK, Kadin M, Coleman CN, Osteen R,
Hellman S (1993) Patterns of presentation of Hodgkin disease.
Cancer 71(6):2062–2071
27. Little MP (2001) Comparison of the risks of cancer incidence and
mortality following radiation therapy for benign and malignant
disease with the cancer risks observed in the Japanese A-bomb
survivors. Int J Radiat Biol 77(4):431–464 (Erratum in: Int J
Radiat Biol 2001 77(6):745–60)
28. van Leeuwen FE, Travis LB (2005) Risk of second malignancy in
patients with selected primary cancers. In: DeVita VT, Hellman
S, Rosenberg SA (eds) Cancer: principles & practice of oncology,
7th edn. Lippincott Williams & Wilkins, Philadelphia, pp 2575–
2602
29. Mack TM, Cozen W, Shibata DK et al (1995) Concordance for
Hodgkin’s disease in identical twins suggesting genetic suscep-
tibility to the young-adult form of the disease. N Engl J Med
332(7):413–418
Radiat Environ Biophys (2008) 47:253–263 263
123
